Dale Muzzey, Chief Scientific Officer of Myriad Genetics Inc, filed a Form 4 on November 9, 2026, disclosing the acquisition of 92,632 time-based stock options granted as a one-time retention award on November 6, 2026.

Key Highlights

  • Reporting person: Dale Muzzey, Chief Scientific Officer of Myriad Genetics Inc (NASDAQ:MYGN)
  • Grant date: November 6, 2026, with a transaction code of A (acquired)
  • Options granted: 92,632 non-qualified stock options at an exercise price of $5.92 per share
  • Vesting schedule: Options vest in full on November 6, 2029, subject to continued service through that date
  • Expiration date: November 6, 2036
  • Exercise price basis: According to the filing, the exercise price equals the closing price of the issuer's common stock on the grant date
  • Price paid: $0 for the derivative security at grant

Dale Muzzey's Retention Option Grant at Myriad Genetics

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Myriad Genetics granted its Chief Scientific Officer, Dale Muzzey, 92,632 time-based non-qualified stock options on November 6, 2026. The filing describes the grant as "a one-time non-qualified stock option granted as a retention award" under the issuer's 2026 Employee, Director and Consultant Equity Incentive Plan. The options were acquired at no cost to the reporting person at grant, with an exercise price of $5.92 per share.

The filing states that the options "vest and become exercisable in full on November 6, 2029, subject to the Reporting Person's continued service through that date and the terms and conditions of the Plan and the applicable award agreement." The underlying security is Myriad Genetics common stock, with 92,632 shares underlying the option. Following the transaction, Muzzey directly holds 92,632 derivative securities beneficially. The expiration date of the options is listed as November 6, 2036, giving a ten-year term from the grant date.

The Form 4 was signed by Justin Hunter on behalf of Dale Muzzey and was filed on November 9, 2026. No non-derivative securities transactions were reported in Table I of the filing.

What Was Disclosed

Myriad Genetics CSO Dale Muzzey received a one-time retention grant of 92,632 non-qualified stock options on November 6, 2026, at an exercise price of $5.92, vesting in full on November 6, 2029, under the company's 2026 equity incentive plan.